2/3

AUG 08 2011

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCA

U.S. Patent AND U.S. Patent OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a) Name of Patentee Docket Number (Optional) Allergan, Inc. Patent Number Date Patent Issued 6,942,980 09-13-2005 Title of Invention METHODS OF IDENTIFYING COMPOUNDS HAVING NUCLEAR RECEPTOR NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES I hereby disclaim the following complete claims in the above identified patent: . The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): 100% 013965/0566 The fee for this disclaimer is set forth in 37 CFR 1.20(d). Patentee claims small entity status. See 37 CFR 1.27. Small entity status has already been established in this case, and is still proper. A check in the amount of the fee is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 010885 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Signed at Irvine 40,283 Registration Number, if applicable John E. Wurst 714-246-5475 Typed or printed name of patentee/ attorney or agent of record Telephone Number 2525 Dupont Address Irvine, CA 92612 USA City, State, Zip Code or Foreign Country as applicable

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to OSPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFK 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form artfor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

08/10/2011 HMARZI1 00000002 010865 you (geologistance in completing the form, call 1-800-PTO-9199 and select option 2.

01 FC:1814

140.00 DA